Related Experiment Video
Updated: Aug 4, 2026

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients
Abstract:
A total of 100 men with organic impotence underwent a trial of intracavernous drug-induced erections with a mixture of papaverine (25 mg./ml.) and phentolamine (0.8 mg./ml.). The response rates, that is functional erections, were 100 per cent in patients with neurogenic impotence, 65.7 per cent in those with vasculogenic impotence, 90 per cent in the undetermined group and 64.7 per cent in the neurogenic/vascular impotence group. Of the responders 79.5 per cent elected to practice self-injection as a method to restore erectile function. The dose required to obtain functional erections in the purely neurogenic impotence group was significantly lower than that required in other groups. Complications were few and included 4 patients with sustained erections that required intervention. Intracavernous injection of vasoactive drugs appears to have promising value in the treatment and differential diagnosis of erectile dysfunction.
More Related Videos
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

